Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

Reexamining NCTN Clinical Trials for Sex Differences in Outcomes and Toxicities in Patients with Neuroendocrine Neoplasms

W Tan;L Cramer;N Vijayvergia;M Lustberg;M Kulke;J Yao;P Kunz NANETS Symposium (North American Neuroendocrine Tumor Society (Nov 21-23, 2024, Chicago, IL), poster

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

M Kulke;F-S Ou;D Niedwiecki;L Heubner;P Kunz;H Kennecke;E Wolin;J Chan;E O'Reilly;J Meyerhardt;A Venook Endocrine-Related Cancer May 9;29(6):335-344

PMid: PMID35324465

Randomized phase II study of everolimus alone (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors, CALGB 80701

M Kulke;D Niedzwiecki;N Foster;B Fruth;H Kennecke;E Wolin;A Venook Journal of Clinical Oncology 33:5s (suppl; abstr 4005); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;